|
Introduction: Nattokinase
Clinical Updates from Doctors Support Its Safety & Efficacy
Doctors Apply Nattokinase in Many Conditions
Six years ago in our special issue on nattokinase, Martin Milner, N.D., announced, “In all my years of research as a professor of cardiovascular and pulmonary medicine, nattokinase represents the most exciting new development in the prevention and treatment of cardiovascular related diseases.” In this issue, Dr. Milner follows up with a detailed report on exactly how he uses nattokinase in his clinical practice. His experience with nearly 300 patients who have taken the enzyme leads him to conclude that: “I believe there is a low-grade chronic coagulation disorder that is very broad-based throughout the United States, as evidenced by the prevalence of cardiovascular disease. Clotting is a key factor in the evolution of chronic disease. With nattokinase, we know how to stop it. Nattokinase helps keep blood optimally flowing more than any other single intervention that I use.”
Back in 2002, we theorized that by dissolving branched fibrin—which coagulates prior to full clot formation—nattokinase might prove uniquely helpful in a range of disorders in which hypercoagulation is involved. This includes atherosclerosis, infertility, high blood pressure, dysmenorrhea, fibromyalgia, deep vein thrombosis, varicose veins, hemorrhoids, and ischemic strokes. We also suggested it would prove helpful in chronic infections, where the body lays down fibrin in an attempt to seal off harmful pathogens. Finally, we concluded that nattokinase could be helpful in slowing many age-associated illnesses, since high fibrin levels create local pathology and ischemia, and block nutrient and oxygen delivery in microcirculation. Six years later, with nattokinase widely in use, firsthand clinical reports from doctors around the country support our hypotheses and the enzyme’s impressive record of efficacy and safety in a wide range of disorders.
In this update we will report on:
- How to diagnose functional clotting problems before obvious clinical disease.
- Why chronic, insidious, low grade clotting can damage blood vessel walls, leading to many of the “diseases” of aging.
- A simple test that can be done in the office to determine whether a patient is clotting at a faster than optimal rate.
- How Coumadin and nattokinase differ.
- The conditions that nattokinase may help.
- Why the over-40 population may already suffer from chronic, subclinical hypercoagulation.
Clotting is a key, often overlooked factor in chronic illness, and with nattokinase, we know how to reverse it. This is where the real treasure of this enzyme lies. Disorders such as heart disease, hypertension, fibromyalgia, chronic infection, inflammatory bowel disease, deep vein thrombosis, may respond to nattokinase. Read article...
Hear how Jonathan Wright, M.D., David Brownstein, N.D., Christopher Deatherage, N.D., and Stephen Hines, N.D. use this powerful, fibrinolytic enzyme. Read article...
Introduction: The Guts and the Glory
Two new developments in gastrointestinal nutrition may change the landscape of gut health and immune function. In this issue we feature two remarkable new nutraceuticals: Zyactinase, a uniquely processed enzyme from kiwi fruit that has a tonic effect on the entire gut, stimulates healthy lactobacilli and other lactic-acid flora, speeds bowel transit time and increases gut motility. We also look at the scientific research on an impressive, new probiotic that functions as a unique prebiotic, selectively stimulating bifidobacteria, the essential, health-promoting flora in our colon.
An astounding 100 trillion micro-organisms thrive and happily beget themselves in our guts. They constitute a microbiome, a kind of super-organism made of microbial life, according to Jeffrey Gordon, M.D., the Dr. Robert J. Glaser Distinguished University Professor at Washington University in St. Louis, and one of the architects of the National Institutes of Health’s Human Microbiome Project. In fact, descendants of the most ancient single-celled organism, the “mother” organism, archaea, can be found in our digestive tract. Fossils of archaea date back to about 3.5 billion years ago. Scientists first isolated archaea from the human intestine in 1982. Our microbiota are evidence not only of evolution’s awe-inspiring creations, but of how closely allied we are with the microbial world.
Research already shows that microbiota choreograph multiple important functions, such as producing essential vitamins, metabolizing toxins, fermenting food in our gut, manipulating our gene activity, influencing the rate at which our gut lining renews itself, and helping regulate everything from blood pressure to obesity. Our microbiota are potent regulators of human health, and our “healthy” native flora help eliminate potential pathogens, and modulate innate and adaptive immune defense mechanisms. Microbiota may one day form the basis of a whole new pharmacopeia. The dawn of that day has already begun, as evidenced in the two new nutraceuticals that together can influence the entire digestive tract in a targeted, powerful way.
Zyactinase has a three-way mode of action that increases stool volume, increases gut motility, and serves as a prebiotic to improve gut microflora. Read article...
Propionic bacteria produce natural biological acids that protect the colon, improve bowel transit time, and selectively stimulate bifidus bacteria. Read article...
|
Interview with Founder
